Metsera initiated as Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Chris Shibutani initiated coverage of Metsera (MTSR) as an Early-Stage Biotech. Metsera is clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics for the treatment of obesity, the analyst tells investors in a research note. The firm says data for the company’s oral GLP-1, MET-224o is expected in late 2025.